About Neutrolis
Neutrolis is a private company based in Cambridge, Massachusetts. It has reported $27,601,145 raised in three offerings on Form D since December 2021.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 20, 2025 | Jul 15, 2025 | $3,500,000of $10.0M target | 1 | $3.5M | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Feb 28, 2025 | Apr 8, 2025 | $964,955of $1.0M target | 9 | $107K | Equity, Common and Series A-4 Preferred StockRule 506(b) | Form D ↗ |
| Sep 10, 2021 | Dec 3, 2021 | $23,136,190of $40.6M target | 28 | $826K | Equity, Series A-1, A-2 and A-3 Preferred StockRule 506(b) | Form D ↗ |
| Total, three offerings | $27,601,145 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Neutrolis's Form D filed Jul 15, 2025.
JS
John Sundy
Director
GC
Gerald Chan
Director
AA
Anthony Aiudi
Executive officer, director and promoter
Also a director at AdvanCell and i2O Therapeutics.
TF
Toby Fox
Executive officer, director and promoter
AR
Abdul Rahamathullah
Executive officer, director and promoter